Innovation Pharmaceuticals Announces License Agreement with Alfasigma S.p.A. for the Development and Commercialization of Brilacidin in Ulcerative Proctitis/Ulcerative Proctosigmoiditis

Author's Avatar
Jul 22, 2019
Article's Main Image

Over $24M in initial and milestone-based payments